Latest Conference Articles

Patients want better control of their atopic dermatitis, and we don’t want them to acquiesce to their disease, explained Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego.

With immunosuppression, self-regulatory mechanisms may start to decrease, and these are the patients who develop skin cancers more frequently, said Rajiv Nijhawan, MD, UT Southwestern Medical Center.

Posters presented at the American Academy of Dermatology Virtual Meeting Experience show ruxolitinib cream was effective at treating atopic dermatitis (AD) regardless of previous treatments and in patients with more severe disease.

Topical application of ruxolitinib cream significantly, and rapidly, decreases pruritus, noted Andy Blauvelt, MD, MBA, dermatologist and clinical study investigator at Oregon Medical Research Center, a dedicated clinical trial site.

There are a number of new biologic options for treating psoriasis, but undertreatment is still a concern, and more long-term data are needed, according to Junko Takeshita, MD, PhD, MSCE, at the National Association of Managed Care Physicians Virtual Spring Managed Care Forum.

Now that investigators have a better understanding of the biological mechanisms of migraine, new treatment and prevention options are making their way to patients and fueling an exciting time for the field, according to a presenter at the National Association of Managed Care Physicians Virtual Spring Managed Care Forum.

With the costs of biologic drugs increasing, biosimilars have emerged as an attractive option for containing costs and expanding access to treatment. However, some barriers to wider uptake still need to be addressed, according to a presentation at the National Association of Managed Care Physicians Virtual Spring Managed Care Forum.

Patients with atopic dermatitis (AD) who received ruxolitinib cream experienced a rapid, clinically meaningful, and sustained improvement in their itch.

For cases of advanced skin cancer that are not candidates for surgery or radiation therapy, we have Hedgehog pathway inhibitors and PD-1 inhibitors, each of which has 2 approved medications, noted Todd Schlesinger, MD, FAAD.

Washout periods are necessary to flush out any lingering effects of drugs that patients are taking before a study, explained Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, George Washington University School of Medicine and Health Sciences.

Metastatic breast cancer has a poor prognosis, but emerging targeted therapies are providing some progress in the treatment of the disease, explained Filipa Lynce, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School.

At a session at the National Association of Managed Care Physicians Virtual Spring Managed Care Forum, an Aetna executive discussed how one employer used the payer's data to see how its workforce was affected by social determinants of health (SDOH).

Microsoft's acquisition of Nuance reflects health care trends of an economy emerging from COVID-19, according to a speaker at the National Association of Managed Care Physicians Virtual Spring Managed Care Forum.

How well, and how in-depth, all parties execute each step can determine how long it will take to reach a finalized agreement, what the relationship will be like after the transaction, and whether the parties will be in legal compliance, speakers noted.

Rajiv Nijhawan, MD, is associate professor of dermatology and Mohs surgeon at UT Southwestern (UTSW) Medical Center and director of the UTSW High Risk Skin Cancer Transplant Clinic, both in Dallas, Texas.

Christine Ko, MD, is professor of dermatology and pathology at Yale University and a presenter of “What's New in Dermatopathology” at this year’s American Academy of Dermatology Virtual Meeting Experience (AAD VMX).

The upcoming 2021 virtual meeting of the American Academy of Dermatology (AAD) will offer more than 75 sessions. Some of the topics to keep an eye out for include treating minority populations, the impact of COVID-19, and patients with cancer.

A changing climate affects every organ system of the body, individual patients, and population-based health, noted Misha Rosenbach, MD, associate professor of dermatology and internal medicine at the University of Pennsylvania.

Three cell and gene therapies were among the drugs included in a specialty drugs pipeline forecast at the Academy of Managed Care Pharmacy 2021 meeting.

Changes to naming conventions and interchangeability labels are just some of the regulatory barriers standing in the way of biosimilar uptake, according to Kaiser Permanente researchers.

Megan Olsen, MPH, principal at Avalere, discussed how gene and cell therapies can offer new treatment options for patients with cancer.

With President Joe Biden marking his 100th day in office at the end of the month, a health policy strategist sat down for a conversation to discuss the new administration’s achievements and challenges.

Atopic dermatitis has a tremendous affect on quality of life, so it’s nice to have more options to treat patients in a different way, noted Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego.

Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management, discussed what evidence they believe could persuade payers to include biosimilars as preferred formulary products.

A poster at the Academy of Managed Care Pharmacy 2021 meeting examined the impact of high-deductible health plans (HDHPs) on access to health care and resource use in the United States and the interaction of race, ethnicity, and income.

Karen Coderre, PharmD, and Madhavi Manduru-Rao, PharmD, detail how CMS' increased weighting for Consumer Assessment of Health Care Providers and Systems surveys impacts Star ratings.

The pandemic reduced visits to specialists last year, which in turn reduced the volume of prescriptions, according to a presentation at the Academy of Managed Care Pharmacy 2021 meeting.

Compared with when Medicare Part D launched, therapies today are more expensive. A panel at the Academy of Managed Care Pharmacy 2021 meeting discussed how the benefit needs to adapt to keep up with the future.